Literature DB >> 8667636

Flt3-ligand production by human bone marrow stromal cells.

M Lisovsky1, S E Braun, Y Ge, H Takahira, L Lu, V G Savchenko, S D Lyman, H E Broxmeyer.   

Abstract

Bone marrow stromal cells are important sources of cytokines and growth factors which participate in regulation of proliferation and differentiation of hematopoietic stem and progenitor cells. Recently flt3/flk-2-ligand (flt3-L), a new growth factor which uses a membrane tyrosine kinase receptor, was cloned. It is expressed in transmembrane and soluble forms and stimulates/co-stimulates proliferation and colony formation of hematopoietic stem/progenitor cells. It has not been reported whether flt3-L is produced by cells of the hematopoietic bone marrow microenvironment. We demonstrate the expression of flt3-L in bone marrow fibroblasts (BMF) and in stromal cells of adherent layers of long-term bone marrow cultures by RT-PCR, Northern blot, immunocytochemistry and FACS analysis. The latter two methods localized flt3-L intracellularly and on cell membranes. Treatment with interleukin-1 alpha increased the expression of flt3-L in BMF. This demonstrates production and modulation of flt3-L in stromal cells of human bone marrow.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8667636

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  14 in total

1.  Innate immune stimuli modulate bone marrow-derived dendritic cell production in vitro by toll-like receptor-dependent and -independent mechanisms.

Authors:  Joan E Downes; Stuart Marshall-Clarke
Journal:  Immunology       Date:  2010-12       Impact factor: 7.397

2.  Repression of Flt3 by Pax5 is crucial for B-cell lineage commitment.

Authors:  Melissa L Holmes; Sebastian Carotta; Lynn M Corcoran; Stephen L Nutt
Journal:  Genes Dev       Date:  2006-04-15       Impact factor: 11.361

Review 3.  Primary Sjögren's syndrome: clinical phenotypes, outcome and the development of biomarkers.

Authors:  Andreas V Goules; Athanasios G Tzioufas
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

4.  Proliferation of human progenitor cells in a long-term culture system is more efficiently sustained by the addition of Flt-3 ligand or megakaryocyte growth and development factor than by Kit ligand.

Authors:  G Cartron; C Binet; O Hérault; C Cailliot; M C Bernard; M H Estienne; N Clément; Ph Colombat; J Domenech
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

5.  Evolution and Potential Subfunctionalization of Duplicated fms-Related Class III Receptor Tyrosine Kinase flt3s and Their Ligands in the Allotetraploid Xenopus laevis.

Authors:  Matthieu Paiola; Siyuan Ma; Jacques Robert
Journal:  J Immunol       Date:  2022-08-05       Impact factor: 5.426

Review 6.  Potential role of sorafenib in the treatment of acute myeloid leukemia.

Authors:  Shahram Mori; Jorge Cortes; Hagop Kantarjian; Weiguo Zhang; Michael Andreef; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2008-12

7.  Bone marrow failure following severe injury in humans.

Authors:  David H Livingston; Devashish Anjaria; Jonathan Wu; Carl J Hauser; Victor Chang; Edwin A Deitch; Pranela Rameshwar
Journal:  Ann Surg       Date:  2003-11       Impact factor: 12.969

8.  Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice.

Authors:  A Staffas; L S Arabanian; S Y Wei; A Jansson; S Ståhlman; P Johansson; L Fogelstrand; J Cammenga; F Kuchenbauer; L Palmqvist
Journal:  Oncogene       Date:  2016-09-12       Impact factor: 9.867

Review 9.  The Biology and Targeting of FLT3 in Pediatric Leukemia.

Authors:  Colleen E Annesley; Patrick Brown
Journal:  Front Oncol       Date:  2014-09-23       Impact factor: 6.244

10.  FMS-Related Tyrosine Kinase 3 Ligand Promotes Radioresistance in Esophageal Squamous Cell Carcinoma.

Authors:  Zuoquan Zhu; Jiahang Song; Junjie Gu; Bing Xu; Xinchen Sun; Shu Zhang
Journal:  Front Pharmacol       Date:  2021-05-10       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.